Clinical Trial Update: Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating siltuximab to prevent CAR T cell–related cytokine release syndrome in CD19-positive non-Hodgkin lymphoma has completed. The study inves…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Sylvant (siltuximab)

Snippet

Sponsor: Timothy Voorhees | Conditions: Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED